Dysmegakaryopoiesis and Transient Mild Increase in Bone Marrow Blasts in Patients With Aplastic Anemia Treated With Eltrombopag May Be Signs of Hematologic Improvement and Not Portend Clonal Evolution

Overview

Journal Am J Clin Pathol

Publisher Oxford University Press

Specialty Pathology

Date 2022 Aug 26

PMID 36018052

Authors

Akira Matsuda

Kazunori Imada

Naoshi Obara

Hiroatsu Iida

Hirohito Yamazaki

Yoshiaki Tomiyama

Koichi Miyamura

Osamu Sasaki

Tetsuo Maeda

Kensuke Ohta

Kensuke Usuki

Yukihiro Tokumine

Kenji Imajo

Yuji Okamoto

Mami Murakami

Shinji Nakao

Affiliations

Soon will be listed here.

Abstract

Objectives: Eltrombopag, a thrombopoietin-receptor agonist, stimulates hematopoiesis in patients with acquired aplastic anemia (AA). Cytomorphologic changes in bone marrow after eltrombopag administration are still unclear. This study examined the effect of eltrombopag on cytomorphologic findings using data from prior phase 2 studies (E1201 and E1202).

Methods: Microscopic examinations were performed in 31 patients with AA (E1201 [n = 21], E1202 [n = 10]). The relationship between hematologic improvement and morphologic findings was also investigated.

Results: In 5 patients (E1201 [n = 3], E1202 [n = 2]), the bone marrow blast count increased after initiation of eltrombopag treatment compared with screening values. The blast count was less than 5%, and the increase in bone marrow blasts was transient in all 4 patients who had bone marrow examinations at follow-up. In 8 patients (E1201 [n = 5], E1202 [n = 3]), dysplastic forms of megakaryocytes were found in the bone marrow following treatment initiation. Dysmegakaryopoiesis of 10% or more was found in 3 patients. None of the patients revealed micromegakaryocytes. Ten patients showed an increase in bone marrow blasts and/or dysmegakaryopoiesis following treatment initiation. Nine of 10 patients showed hematologic improvement in 1 or more lineages.

Conclusions: Dysmegakaryopoiesis without micromegakaryocytes and a transient increase of less than 5% in bone marrow blast count may be signs of hematologic improvement with eltrombopag for patients with AA.

References

Sun H, Tsai Y, Nowak I, Liesveld J, Chen Y . Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res. 2012; 9(2):77-86. PMC: 3412938. DOI: 10.1016/j.scr.2012.05.001. View

Kantarjian H, Fenaux P, Sekeres M, Szer J, Platzbecker U, Kuendgen A . Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol. 2018; 5(3):e117-e126. DOI: 10.1016/S2352-3026(18)30016-4. View

Townsley D, Desmond R, Dunbar C, Young N . Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. Int J Hematol. 2013; 98(1):48-55. PMC: 4144663. DOI: 10.1007/s12185-013-1352-6. View

Yamazaki H, Ohta K, Iida H, Imada K, Obara N, Tokumine Y . Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy. Int J Hematol. 2019; 110(2):187-196. DOI: 10.1007/s12185-019-02683-1. View

Townsley D, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O . Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med. 2017; 376(16):1540-1550. PMC: 5548296. DOI: 10.1056/NEJMoa1613878. View

Singal R, BELLIVEAU R . Quantitation of megakaryocytes in normal bone marrow. Anal Quant Cytol Histol. 1988; 10(1):33-6. View

Olnes M, Scheinberg P, Calvo K, Desmond R, Tang Y, Dumitriu B . Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012; 367(1):11-9. PMC: 3422737. DOI: 10.1056/NEJMoa1200931. View

Killick S, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A . Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2015; 172(2):187-207. DOI: 10.1111/bjh.13853. View

Imada K, Obara N, Iida H, Imajo K, Maeda T, Usuki K . Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan. Intern Med. 2020; 60(8):1159-1168. PMC: 8112980. DOI: 10.2169/internalmedicine.6063-20. View

10.

Yamazaki H, Nakao S . Border between aplastic anemia and myelodysplastic syndrome. Int J Hematol. 2013; 97(5):558-63. DOI: 10.1007/s12185-013-1324-x. View

11.

Bacigalupo A . How I treat acquired aplastic anemia. Blood. 2017; 129(11):1428-1436. DOI: 10.1182/blood-2016-08-693481. View

12.

Lum S, Grainger J . Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Des Devel Ther. 2016; 10:2833-2843. PMC: 5028092. DOI: 10.2147/DDDT.S95715. View

13.

Desmond R, Townsley D, Dumitriu B, Olnes M, Scheinberg P, Bevans M . Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2013; 123(12):1818-25. PMC: 3962161. DOI: 10.1182/blood-2013-10-534743. View

14.

Sun L, Babushok D . Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood. 2020; 136(1):36-49. PMC: 7332901. DOI: 10.1182/blood.2019000940. View

15.

Clucas D, Fox L, Wood E, Hong F, Gibson J, Bajel A . Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. Intern Med J. 2018; 49(2):152-159. DOI: 10.1111/imj.14140. View

16.

Tuzuner N, Bennett J . Reference standards for bone marrow cellularity. Leuk Res. 1994; 18(8):645-7. DOI: 10.1016/0145-2126(94)90048-5. View

17.

Erickson-Miller C, Kirchner J, Aivado M, May R, Payne P, Chadderton A . Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res. 2010; 34(9):1224-31. DOI: 10.1016/j.leukres.2010.02.005. View

18.

Kantarjian H, Fenaux P, Sekeres M, Becker P, Boruchov A, Bowen D . Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2009; 28(3):437-44. DOI: 10.1200/JCO.2009.24.7999. View

19.

Desmond R, Townsley D, Dunbar C, Young N . Eltrombopag in aplastic anemia. Semin Hematol. 2015; 52(1):31-7. PMC: 4293077. DOI: 10.1053/j.seminhematol.2014.10.002. View

20.

Oliva E, Alati C, Santini V, Poloni A, Molteni A, Niscola P . Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017; 4(3):e127-e136. DOI: 10.1016/S2352-3026(17)30012-1. View